【佳学基因检测】鉴定和验证失巢凋亡相关基因特征以预测胶质母细胞瘤的临床特征、干性、IDH 突变和免疫过滤

做个基因检测需要多少钱介绍

综述dota2吧雷电竞 基因学知识要点记录《Front Immunol》在. 2022 Aug 25;13:939523.发表了一篇题目为《鉴定和验证失巢凋亡相关基因特征以预测胶质母细胞瘤的临床特征、干性、IDH 突变和免疫过滤》dota2吧雷电竞 dota2吧雷电竞 治疗基因检测临床研究文章。该研究由Zhongzheng Sun, Yongquan Zhao, Yan Wei, Xuan Ding, Chenyang Tan, Chengwei Wang 等完成。促进了dota2吧雷电竞 的正确治疗与个性化用药的发展，进一步强调了基因信息检测与分析的重要性。

肿瘤靶向药物及正确治疗临床研究内容关键词：

失巢凋亡,胶质母细胞瘤,免疫疗法,泛癌分析,干性指数,肿瘤微环境

肿瘤靶向治疗基因检测临床应用结果

背景：胶质母细胞瘤 (GBM) 是成人中贼突出、贼具侵袭性的原发性脑肿瘤。失巢凋亡是一种特定形式的程序性细胞死亡，在肿瘤侵袭和转移中起关键作用。抗失巢凋亡因子的存在与肿瘤侵袭性和耐药性有关。方法：非负矩阵分解算法被用于对集成数据集进行有效的降维。分析了两个集群之间的肿瘤微环境 (TME)、干性指数和临床特征的差异。利用差异分析、加权基因共表达网络分析（WGCNA）、单变量Cox回归、贼小先进收缩和选择算子回归筛选预后相关基因并构建风险评分模型。进行免疫组织化学以评估临床标本中代表性基因的表达。在GBM和泛癌中评估风险评分与TME、干性、临床特征和免疫治疗反应之间的关系。结果：根据失巢凋亡相关基因表达确定了两个明确的聚类。分配到 C1 的 GBM 患者的特征是总生存期缩短、抑制性免疫浸润水平较高和干性指数较低。我们进一步构建了一个风险评分模型来量化失巢凋亡相关基因的调控模式。较高风险评分组的特点是预后不良、抑制性免疫细胞浸润和分化表型，而较低风险评分组表现出相反的效果。此外，较低风险评分组的患者表现出更高频率的异柠檬酸脱氢酶 (IDH) 突变和对免疫治疗更敏感的反应。进行了药物敏感性分析，揭示高风险组可能从靶向 PI3K/mTOR 信号通路的药物中获益更多。结论：我们揭示了失巢凋亡相关基因与临床特征、TME、干性、IDH 突变和免疫治疗之间的潜在关系，以及阐明了它们的治疗价值。关键词：失巢凋亡；胶质母细胞瘤;免疫疗法；泛癌分析；干性指数；肿瘤微环境。

肿瘤发生与反复转移国际数据库描述：

Background: Glioblastoma (GBM) is the most prominent and aggressive primary brain tumor in adults. Anoikis is a specific form of programmed cell death that plays a key role in tumor invasion and metastasis. The presence of anti-anoikis factors is associated with tumor aggressiveness and drug resistance.Methods: The non-negative matrix factorization algorithm was used for effective dimension reduction for integrated datasets. Differences in the tumor microenvironment (TME), stemness indices, and clinical characteristics between the two clusters were analyzed. Difference analysis, weighted gene coexpression network analysis (WGCNA), univariate Cox regression, and least absolute shrinkage and selection operator regression were leveraged to screen prognosis-related genes and construct a risk score model. Immunohistochemistry was performed to evaluate the expression of representative genes in clinical specimens. The relationship between the risk score and the TME, stemness, clinical traits, and immunotherapy response was assessed in GBM and pancancer.Results: Two definite clusters were identified on the basis of anoikis-related gene expression. Patients with GBM assigned to C1 were characterized by shortened overall survival, higher suppressive immune infiltration levels, and lower stemness indices. We further constructed a risk scoring model to quantify the regulatory patterns of anoikis-related genes. The higher risk score group was characterized by a poor prognosis, the infiltration of suppressive immune cells and a differentiated phenotype, whereas the lower risk score group exhibited the opposite effects. In addition, patients in the lower risk score group exhibited a higher frequency of isocitrate dehydrogenase (IDH) mutations and a more sensitive response to immunotherapy. Drug sensitivity analysis was performed, revealing that the higher risk group may benefit more from drugs targeting the PI3K/mTOR signaling pathway.Conclusion: We revealed potential relationships between anoikis-related genes and clinical features, TME, stemness, IDH mutation, and immunotherapy and elucidated their therapeutic value.Keywords: anoikis; glioblastoma; immunotherapy; pan-cancer analysis; stemness index; tumor microenvironment.